Moreover, injection of PKC inhibitor significantly increases Aβplaques in APP/PS1 mice, an animal model of Alzheimer’s disease, which further identify the evidence that PKC signaling is involved in regulation TFEB, thereby facilitating lysosomal clearance and mediating cellular adaptation to many extracellular cues [74, 75] (Fig. 3). This evidence concerns the gene PRRT2 and early-onset autosomal dominant Alzheimer disease.